FDA Approves Interchangeable Ranibizumab Biosimilar
Quick Facts
What Is Ranibizumab-hkdz and How Does It Work?
Ranibizumab is an antibody fragment injected into the eye to inhibit vascular endothelial growth factor A, or VEGF-A. Excess VEGF signaling can promote abnormal blood-vessel growth and leakage in retinal disorders, leading to swelling, bleeding and progressive vision loss. Blocking this pathway can reduce retinal fluid and help preserve or improve vision in appropriately selected patients.
A biosimilar is not a conventional generic because biologic medicines are produced in living systems and cannot be copied identically in the way small-molecule drugs can. FDA approval requires extensive analytical evidence showing that the biosimilar is highly similar to its reference product, with no clinically meaningful differences in safety, purity or potency.
What Does Interchangeable Biosimilar Status Mean?
Under US law, every interchangeable product is a biosimilar, but not every biosimilar is designated interchangeable. Interchangeability does not mean that one medicine is clinically superior; it indicates that the FDA has determined the product satisfies the statutory standard for substitution, subject to applicable state pharmacy laws.
The practical effect may be different for eye injections than for medicines routinely dispensed at retail pharmacies because intravitreal treatments are generally selected, purchased and administered by specialist practices. Insurer formularies, clinician experience, inventory systems and patient-specific considerations may therefore influence adoption alongside the interchangeable designation.
Why Do Vial and Prefilled-Syringe Options Matter?
Prefilled syringes may reduce preparation steps compared with drawing medicine from a vial, while vials can remain useful for practices whose established workflows are built around that format. Either presentation must be handled with meticulous sterile technique because intravitreal injections carry uncommon but serious risks, including endophthalmitis, retinal detachment and increased intraocular pressure.
Additional biosimilar competition may place downward pressure on acquisition costs, but an FDA approval alone does not guarantee lower out-of-pocket spending. Coverage policies, negotiated prices and billing arrangements all affect what patients and health systems ultimately pay. Treatment decisions should remain based on the approved prescribing information, the retinal diagnosis and an ophthalmologist's assessment.
Frequently Asked Questions
No clinically meaningful difference in safety, purity or potency is expected. FDA approval requires evidence that the biosimilar meets rigorous similarity standards, while interchangeability requires additional regulatory findings.
Substitution rules vary by state, insurer and care setting. Because ranibizumab is injected into the eye by a clinician, patients should discuss any proposed switch with their retinal specialist.
No. They may streamline preparation, but intravitreal injection still requires sterile technique and monitoring for pain, worsening redness, light sensitivity, new floaters or declining vision.
References
- U.S. Food and Drug Administration. Biosimilar and Interchangeable Biologics.
- U.S. Food and Drug Administration. Purple Book: Database of Licensed Biological Products.
- Eye Care Network and Modern Retina. FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes. July 2026.